Apyx Medical Q1 2025 Earnings Report

Apyx Medical EPS Results

• Actual EPS: -$0.10
• Consensus EPS: -$0.13
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Apyx Medical Revenue Results

• Actual Revenue: $9.43 million
• Expected Revenue: $9.39 million
• Beat/Miss: Beat by +$42.00 thousand
• YoY Revenue Growth: N/A

Apyx Medical Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 8:00AM ET

Apyx Medical (NASDAQ:APYX), an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx Medical Q1 2025 Earnings Call Transcript

Key Takeaways

• APYX reported first-quarter revenue of $9.4 million, down 8% year-over-year; Advanced Energy sales rose 6% to $7.9 million while OEM product sales declined 44.7%.
• Operating expenses fell to $8.7 million (from $12.6 million), driving a net loss of $4.2 million versus $7.6 million last year and reducing cash burn to $0.7 million in Q1.
• Management highlighted a surge in demand from patients on GLP-1 weight-loss drugs and positioned Renuvion—the only FDA-cleared post-liposuction skin-tightening device—as uniquely suited for treating loose skin.
• The company’s AON all-in-one body-contouring platform, submitted to the FDA in December, is slated for a back-half 2025 launch with 20 early adopters lined up to drive equipment sales and expand the addressable market.
• 2025 guidance was reaffirmed, with total revenue expected at $47.6 million–$49.0 million, Advanced Energy $39.6 million–$41.0 million, OEM around $8 million, ~60% gross margin, operating expenses ≤$40 million and cash runway into 2027.

Presentation

[Operator]

Ladies and gentlemen, good morning, and welcome to the Apyx Medical First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci Advisors. Please go ahead.

[Jeremy Feffer, Managing Director at LifeSci Advisors, LLC]

Thank you, and welcome everyone to our first quarter twenty twenty five earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer and Matt Hill, Chief Financial Officer of APICS. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10 ks, our most recent 10 Q filing, and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward looking statements as a result of new information, future events or otherwise.

[Jeremy Feffer, Managing Director at LifeSci Advisors, LLC]

This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non GAAP financial measures. Reconciliations of those non GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, APICS Medical's President and Chief Executive Officer. Please go ahead.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will be providing a review of our performance in the first quarter of twenty twenty five, and then I will turn the call over to Matt for a review of our first quarter financial results, as well as our full year 2025 guidance. We will then open the call for your questions. Let me start with a review of our first quarter performance. We reported total revenue of $9,400,000 for the quarter, a decrease of 8% compared to $10,200,000 for the same period last year.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

While sales of our OEM products decreased as expected, sales of our Advanced Energy products increased 6% to $7,900,000 for the first quarter of twenty twenty five compared with last year's period. This reflects a building trend we have seen over the past year with stronger sales of single use handpieces in The United States. We also continue to see demand for capital equipment stabilize with increases year over year for two consecutive quarters in The US. We believe this speaks to the benefits offered by Renuvion as the only FDA cleared device for use after liposuction, as well as its ability to treat loose and lax skin. Digging further into our financial performance for the quarter, I want to point out that our team delivered these solid top line results, somewhat defying the industry.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

We also implemented significant cost cutting measures and a restructuring program that right sized our operations just six months ago. I think these initial results show this program is achieving its intended outcomes of reducing cost, reducing cash burn, and speaks to the dedication of our commercial strategy and vision for APEX. Matt and I are very appreciative of everyone's effort, and I am truly excited about the direction we are heading. We've laid a strong foundation that is energizing and setting the stage for meaningful growth, innovation and impact. There are persistent macroeconomic headwinds impacting the global aesthetic space.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

At the same time, we believe the primary impact on the market is coming from the explosive growth of GLP-1s. We estimate that over fifteen million patients are currently using GLP-one drugs, many of which we believe will seek treatment for loose and lax skin due to the associated rapid weight loss. As I have mentioned previously, we are still in the early innings of this market when it comes to our role in serving these patients' needs as they meet their goal weight. In fact, Doctor. Randy Boyatt in her podcast cited a study of ten twenty eight GLP-one patients across four twenty four clinics examining the top 10 aesthetic treatments after medical weight loss.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Number one was skin tightening treatments at 63, and number two was body contouring fat reduction at fifty two percent. As the only true surgical aesthetics company, we believe we are uniquely positioned to take advantage of this burgeoning tailwind. This brings me to our Renuvion offering. We believe this minimally invasive surgical procedure is the best treatment option to address loose and lax skin, providing a durable and transformational result. It is our belief that Renuvion should be the standard of care for all patients, including those who have lost significant weight as a result of GLP-one drugs.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Our results are supported by long term data. Just last month, we announced the publication of two peer reviewed articles on two separate clinical studies that evaluated the use of Renuvion during body contouring procedures, including lipoabdominoplasty following significant weight loss. In these studies, the authors reported that patients in the Renuvion group demonstrated improvements in abdominal skin laxity and excess skin, along with higher satisfaction scores. These papers highlight the use of Renuvion in combination with lift procedures, which are growing more than 20%. And please keep in mind that these newly published data simply reinforce a larger and growing body of evidence supporting the safety and utility of Renuvion in aesthetic body contouring.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

For further validation, we are excited to announce just a few weeks ago that Renuvion won the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener. As part of this process, new beauty editors tested thousands of products leading up to the fifteenth annual awards issue with a goal of selecting the most innovative beauty products, treatments, and trends. They also collaborate with board certified doctors and medical experts to determine the most effective, results driven, in office treatments and post procedure essentials. And so we are honored to have our game changing technology receive this accolade by such a trusted authority in the aesthetic space. Regarding our direct to consumer marketing strategy, our program continues to deliver outstanding results generating significant reach, views and PR beyond our expectations.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

As I have mentioned previously, as part of this program, we have successfully leveraged several influencers who each bringing a unique voice and engaged audience to our campaign. Most recently, we announced the appointment of Dolores Cantina as the Chief of Confidence for the brand's Renew You consumer marketing campaign, which exemplifies the brand's ability to reshape bodies and lives. As a beloved personality of The Real Housewives of New Jersey, Dolores provides a real take on the problem patients face with loose skin and the power of our body contouring technology. She is a powerful advocate for choosing board certified plastic or cosmetic surgeons for treatments and procedures. This overlaps really well with our messaging that Renuvion is the number one trusted body contouring technology among these doctors, along with clinical data, and we believe she will be a valuable member of the APICS team.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Turning to our development pipeline, we are very excited to have introduced our AON body contouring on our third quarter call following the submission of the five ten to the FDA in December. This all in one platform seamlessly integrates Renuvion, ultrasound assisted liposuction, power assisted liposuction, infiltration, aspiration, electrocoagulization, and fat transfer into a single streamlined device. Considering the major shifts in the market with rapid adoption of GLP-1s, we believe AON is a game changer for surgeons that will differentiate us and position Apyx as their surgical partner. Our goal for the next few years is to be able to walk into almost any surgeon's practice and see Aon position in the heart of their Operating Room pending clearance. In late March, we offered an early look at Aon system to board certified plastic and cosmetic surgeons during the aesthetic meet in Austin, Texas, which is considered the premier event in aesthetics.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

I am excited to report that the feedback exceeded all expectations, as many of the physicians we spoke with confirmed that the AON would be a welcome addition to many of their practices and provided for all of their surgical needs. Regarding timing, we are preparing for a planned launch of Aeon in the back half of twenty twenty five pending clearance. We expect the introduction of the Aeon system to the market will help kick start our equipment sales growth as we have an opportunity to capture new market share and expand our total addressable market in aesthetic surgery. I will now turn the call over to Matt for a review of our first quarter twenty twenty five financial results in more detail, along with our financial guidance for 2025.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

Thanks, Charlie. Before I get started, please note that all references to first quarter financial results will be on a GAAP and year over year basis unless otherwise noted. As Charlie mentioned, total revenue for the first quarter twenty five decreased 7.9% to $9,400,000 compared to $10,200,000 in the prior year period. Revenue for the Advanced Energy segment increased 5.8% to 7,900,000 as a result of increased volume of single use handpieces domestically, domestic and international sales of upgrades of the APYX-one console and domestic sales of new generators. These increases were partially offset by lower average selling price of generators to domestic customers and a general decrease in international sales.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

OEM segment sales decreased 44.7% or approximately $1,200,000 for the first quarter of twenty five when compared to the first quarter of twenty four. The decrease in OEM sales was due to decrease in sales volume to existing customers, excluding Symmetry Surgical under our ten year generator manufacturing and supply agreement. Domestic revenue decreased 3.4% year over year to $6,700,000 and international revenue decreased 17.7% year over year to $2,700,000 As a reminder, there's somewhat of a seasonality to the medical device business, where quarterly revenue is normally the lowest in Q1 and Q3, and the highest in Q2 and Q4. Gross profit for the first quarter 'twenty five decreased to $5,700,000 compared with the $5,900,000 in the prior year period. Gross profit margin for the first quarter 'twenty five was 60.1% compared to 58.1% in the prior year period.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

The increase in gross profit margins was primarily attributable to the mix between our segments with advanced energy comprising a higher percentage of total sales and geographic mix within our advanced energy segment, with domestic sales comprising a higher percentage of total sales. These increases were partially offset by a decrease in the average selling price of generators to domestic customers and product mix within our OEM segment. With respect to tariffs, we are actively monitoring trade policy and tariff announcements, including the recent executive orders issued by the US Federal Administration regarding tariffs on imports from various countries. At this time, the overall impact on our business related to these or any other tariffs that may be imposed remains uncertain and depends on multiple factors. Moving on to operating expenses, which decreased to $8,700,000 for the first quarter twenty five, compared to $12,600,000 in the prior year period.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

The decrease in operating expenses was driven by $1,600,000 decrease in salaries and related costs, a $1,500,000 decrease in selling and general administrative expenses, a $600,000 decrease in research and development expenses, and a $100,000 decrease in professional services expenses. Loss from operations decreased 3,600,000 or 54% to $3,100,000 Net loss attributable to shareholders was $4,200,000 or $0.10 per share for the first quarter twenty five, compared with $7,600,000 or $0.22 per share in the prior year period. Adjusted EBITDA loss decreased 54% to $2,400,000 compared to $5,300,000 in the first quarter of twenty four. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non GAAP adjusted EBIT loss in our earnings press release. For the three months ended 03/31/2025, cash used in operating activities decreased to $700,000 compared to $6,300,000 used in the prior year period.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

We were pleased with the cash and working capital management in the first quarter, and we expect to return to more normalized cash burn for the balance of 'twenty five. As of March 3125, the company had cash and cash equivalents of $31,000,000 compared to $31,700,000 as of December 3124. We believe, based on our projections, including uptake of the AIM platform, working capital management and our strict cost controls, we will yield cash into 2027. Turning to a review of our '25 guidance, which we reaffirmed in our first quarter 'twenty five financial results press release issued earlier today, for the twelve months ending December '5, we expect total revenue in the range of $47,600,000 to $49,000,000 as compared to $48,100,000 for the year ended 12/31/2024. Our revenue guidance assumes Advanced Energy revenue in the range of $39,600,000 to $41,000,000 as compared to $38,600,000 for the year ended December 3124.

[Matthew Hill, Chief Financial Officer at Apyx Medical]

OEM revenue is expected to come in at approximately $8,000,000 as compared to $9,500,000 for the year ended December 3124. We see Q2 OEM revenue to be similar to Q1, with the balance of the $8,000,000 to be allocated to the back half of the year. We still anticipate gross margins of approximately 60% for the year and a total operating expenses not to exceed $40,000,000 This completes our prepared remarks. Charlie and I will now open the call for questions. Operator?

[Operator]

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by one on your touch tone phone. You will hear a prompt that your hand has been raised. First question comes from Matt Ewitt with Craig Hallum Capital Group. Please go ahead.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

Good morning. Thank you for taking the questions. Obviously, it's it's nice to hear that you're seeing some stability on the generator side. One of the opportunities with the the Aon platform, was that for the practices to to obtain one of those, they're gonna have to kinda get in queue. And to do that, you were gonna give priority to those that had upgraded to the APXONE console.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

How progressing? Are you seeing customers enroll for that? And what does the pipeline look on that side?

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Yes. Thanks, Matt. I appreciate the question. Look, we're not going to comment on the pipeline for Aon yet. We're still waiting clearance from the FDA and so we'll have plenty of time to update everybody on Aon and what's going on there.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

But obviously the announcement of Aon gives doctors and clinicians a huge impetus to upgrade to the APICS-one because of the excitement around Aon. And so we're very happy with what we're seeing in the marketplace regarding that.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

Yeah. And I apologize. I I I could have been a little more clear. I was asking about the Apex One console, the the upgrades to just get in queue, for Aon. I was just curious if you were seeing increased demand, for the Apex One ahead of that.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Yeah, no that is actually what I tried to answer and and the answer to that is you know we're happy with what we're seeing for that is the upgrade is people upgrading to the APYX one and waiting for AON.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

Got it. Alright. And then as far as there was going to be a soft launch later this year, I think last call you had kind of mentioned that you you kind of had a list, but have you kind of solidified the list of of practices that will be receiving Aon, and, you know, are they getting set up? Kind of walk through the process once you do receive approval from the FDA, what that that kind of first batch of KOLs, what that'll look like?

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Yeah, so we do, we have that list all solidified. We've got 20 Aeon ambassadors throughout The United States that are ready to go once we get clearance. Obviously we would install the systems, get them and their staffs trained on everything and then they would obviously start performing cases and give us feedback and all of that and that clock starts you know, when we get when we get clearance and then when, you know, we get everything installed and ready to go. But we are we we are making great progress with all of that. And now it's just a matter of of of waiting.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

Understood. And one last one, and I know you touched on this a little bit in your prepared remarks, but obviously, of mind for a lot of investors recently has been tariffs. Maybe just remind everyone where you're obtaining your products from and what if anything would need to be done to mitigate any potential tariff impact? Thank you.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Yes, no thanks Matt. So look we get we've got a supply chain where we get parts from all over the world but one of the advantages that we have as a company is we have manufacturing both in The United States and we have manufacturing both in Sofia, Bulgaria. So based on what the environment is and what the best path for us, we can adjust manufacturing between the two facilities. And so we do have a little bit of flexibility when it comes to that.

[Matt Hewitt, Senior Research Analyst at Craig-Hallum]

That's great. Thank you.

[Operator]

Next question comes from Sam Iberg with BTIG. Please go ahead.

[Sam Eiber, Vice President and Medical Technology Analyst at BTIG]

Hey, good morning, Charlie and Matt. Thanks for taking the questions here. Maybe I can just follow-up on the last question on tariffs. And obviously, I know there's a lot of moving parts here. But I guess as currently contemplated today, any way to size the impact to margins at this point?

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

So if Matt's prepared remarks, he that we're still expecting gross margins to be around 60% for the entire year, I think that's what we said at the beginning of the year and all of that would impact everything that we know right now based on the current situation.

[Sam Eiber, Vice President and Medical Technology Analyst at BTIG]

Okay, so it sounds like pretty minimal impact at this point. And then, maybe I can use my follow-up here on just how you're thinking about investments to support the Aon launch. Obviously, I know you're keeping a close eye on cash burn and operating expenses, but how are you positioning investments to support this launch while also preserving capital here?

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Yeah, look, obviously expense control and cash management is incredibly important to us, but it's not at the expense of the Aon launch and everything that we've contemplated into our budget and the investments that we're making is there to support Aon and to be able to grow that. Remember we think that Aon is a huge differentiator for us at APICS Medical and makes us a true partner for the surgeons and we've got plans for how not only are we going to use capital to build new aeons but obviously part of the social strategy to talk about that and everything else. So it's always been contemplated in there, We are going to do our best to keep managing expenses and managing our cash burn but like I said it won't be at the expense of the launch of Aon.

[Sam Eiber, Vice President and Medical Technology Analyst at BTIG]

Okay, very good. Thanks for taking the questions.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

You bet.

[Operator]

There are no further questions. Please continue.

[Charles Goodwin, President and Chief Executive Officer at Apyx Medical]

Thank you, everyone.

Participants

Executives

• Charles Goodwin, President and Chief Executive Officer
• Matthew Hill, Chief Financial Officer

Analysts

• Jeremy Feffer, Managing Director at LifeSci Advisors, LLC
• Matt Hewitt, Senior Research Analyst at Craig-Hallum
• Sam Eiber, Vice President and Medical Technology Analyst at BTIG